December 20, 2024

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

“Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chir...

The ASCO Post

December 20, 2024

Courts, Congress keep Corporate Transparency Act in flux

Dentists potentially impacted by the CTA are receiving mixed messages about whether they need to file for beneficial ownership.

ADA News

December 20, 2024

Riluzole Shows Promise in Reversing Cognitive Decline from Radiation Therapy

Boosting brain-derived neurotrophic factor (BDNF) with riluzole may mitigate cognitive dysfunction from radiation therapy.

Conexiant

December 20, 2024

Small HCQ Study Falls to Retraction

When combining hydroxychloroquine with azithromycin, researchers reported 100% virological cure by day 6 compared to 57.1% with hydroxychloroquine alone and 12.5% in controls - though the now-retracted study's small sample included just 6 patients receiving both drugs.

Conexiant

December 20, 2024

Bio-interventional Cyclodialysis with Allograft Scleral Reinforcement for OAG

The combined procedure decreased IOP and improved BCVA.

Conexiant

December 20, 2024

In Treatment of Transplant-Ineligible Myeloma, Addition of Isatuximab Improves Outcomes

In the phase III IMROZ trial, the addition of the anti-CD38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was more effective than VRd alone as initial therap...

The ASCO Post

December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 20, 2024

New Arthritis Findings Span Two Decades

New research reveals increased risk factors for psoriatic arthritis in patients with juvenile idiopathic arthritis over an 18-year study period in the Nordic region.

Conexiant

December 20, 2024

Use of Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia

In a German phase III trial (CLL12), reported in the Journal of Clinical Oncology, Langerbeins et al found that ibrutinib prolonged the time to symptomatic disease in patients with early-stage chronic...

The ASCO Post